Treatment with either glucocorticoids, methotrexate, anakinra, or tocilizumab has been examined. Anakinra has been shown to resolve the clinical features of the disease in 87% of patients. It also induces remission in half of corticosteroid-resistant patients. The results of another study were similar, with half of the patients responding to treatment with Anakinra. Canakinumab, an antibody to interleukin-1 beta, is indicated for treatment in patients who respond poorly to other treatments.
Systemic-onset juvenile idiopathic arthritis
Juvenile idiopathic arthritis
Childhood arthritis
Sjögren–Larsson syndrome
Sjögren syndrome
Reactive arthritis
Psoriatic arthritis
CREST syndrome